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Abstract 
Introduction: In inflammatory bowel disease (IBD), inflammation is sustained by an 
exaggerated response of lymphocytes. This results from enhanced expression of anti-
apoptotic BCL-2 and BCL-XL associated with a diminished turnover. Azathioprine 
(AZA) directly targets BCL-2 family-mediated apoptosis. We investigated whether the 
BCL-2 family expression pattern could be used to predict treatment response to AZA 
and determined whether BCL-2 inhibitor A-1211212 effectively diminishes 
lymphocytes and ameliorates inflammation in a model of colitis. 
Methods: BCL-2 family expression pattern was determined by next generation 
sequencing (NGS). BCL-2 inhibitor was administered orally to Il-10-/- mice. 
Haematological analyses were performed with an ADVIA 2120 and changes in immune 
cells were investigated using qPCR and FACS. 
Results: We determined similar expression levels of BCL-2 family members in patients 
with remission and patients refractory to treatment, showing that BCL-2 family 
expression can not predict AZA treatment response. Expression was not correlated 
with the modified Truelove and Witts activity index (MTWAI). BCL-2 inhibitor initiated 
cell death in T cells from patients refractory to AZA and reduced lymphocyte count in 
Il-10-/-. FACS revealed diminished CD8+ T cells upon BCL-2 inhibitor in Il-10-/- without 
influencing platelets. Tnf, Il1β, Ifnγ and Mcp1 was decreased. A-1211212 positively 
altered the colonic mucosa and ameliorated inflammation in mice. 
Conclusions: The expression pattern of BCL-2 family genes does not predict AZA 
treatment response in IBD. Pro-apoptotic BCL-2 inhibitor A-1211212 diminishes 
lymphocytes and ameliorates colitis in Il-10-/- mice without inducing thrombocytopenia. 
BCL-2 inhibition could be a new therapy option for patients refractory to AZA.   
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INTRODUCTION 
Inflammatory bowel disease (IBD) affects about one in a hundred and fifty people in 
the industrialized world. IBD is characterized by a chronic inflammation of the intestinal 
wall and comprises two main conditions, ulcerative colitis (UC) and Crohn’s disease 
(CD). The inflammatory state in IBD is sustained by an exaggerated response of T-
lymphocytes to luminal antigens, which is associated with an increased resistance to 
apoptosis in these cells (1). The B-cell lymphoma (BCL)-2 family plays a critical role in 
the control of immune responses by regulating the expansion and contraction of the 
activated lymphocyte population via apoptosis. Pro-survival BCL-2 family members 
(BCL-2, BCL-XL, BCL-, MCL-1 and A1) interact with pro-apoptotic BCL-2 family 
members (e.g. BAX and BAK from the BAX group, and BIM and BMF from the BH3-
only group), and induce or abolish apoptosis. All BCL-2 family members share a 
common BH3 domain. The balance of interactions between BCL-2 family members 
determines the celullar lifespan. Most activated T cells die at the end of a T cell 
response, which coincides with decreased levels of BCL-2 in vivo (2, 3). In patients 
suffering from IBD, the lifespan of antigen-primed and activated T cells is extended, 
and an abnormal population of activated T cells is retained within the mucosal 
compartment (1, 4, 5). Enhanced expression of the anti-apoptotic BCL-2 is found in 
lamina propria lymphocytes from inflamed tissue in CD patients (4). These cells also 
present activation of the STAT-3 signalling pathway, which mediates the expression of 
anti-apoptotic BCL-2 and BCL-XL (6). Resistance of T cells to apoptotic signals is 
correlated with an increase in BCL-2 expression in CD patients (4). In contrast, 
apoptosis of anti-inflammatory regulatory T cells is reduced in IBD patients (7).  
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Medical therapies that regulate proliferation and contraction of lymphocyte populations 
are directly linked to the BCL-2 family-mediated apoptosis (8, 9). Azathioprine (AZA) 
and its metabolite 6-mercaptopurine (6-MP) are immunosuppressive agents that 
interfere with T cell proliferation via its metabolite 6-thioguaninnucleotide. AZA therapy 
reduces blood and lamina propria natural killer cells by promoting apoptosis (10). AZA 
supresses BCL-XL, thereby leading to apoptosis through the mitochondria-mediated 
apoptosis pathway (11). Likewise, other central therapeutic agents, such as 
sulfasalazine (12), glucocorticoids (13) and anti-TNF antibodies (14-16) are potent pro-
apoptotic agents modulating the activity of BCL-2 family members. 
Boosting the initiation of cell death in apoptosis-resistant lymphocytes could improve 
the success of medical therapy. A number of BH3 mimetics that directly antagonize 
BCL‐2 proteins are available. ABT-737 is a potent inhibitor of BCL-2, BCL-XL and BCL- 
ω (17, 18), and disrupt the interactions of BCL-2 family proteins, resulting in apoptosis 
in lymphoma and other blood cancers (19). Because of its unfavorable pharmacologic 
properties, ABT-737 is not appropriate for clinical trials, while its orally bioavailable 
derivative navitoclax (ABT-263), which also inhibits BCL-2, BCL-XL and BCL-ω, is an 
experimental anti-cancer drug without off-target effects (20). Inhibition of BCL-XL may 
be responsible for the observed reduction of platelet lifespan and may also cause 
thrombocytopenia upon navitoclax treatment. To overcome side effects, BCL-2 
selective BH3 mimetics were developed. Venetoclax (ABT-199, trade names 
Venclexta and Venclyxto, AbbVie) inhibits BCL-2 selectively, constituting the first 
substance from the chemical class of BCL-2 inhibitors approved by the FDA. 
Venetoclax is an oral drug for the treatment of chronic lymphocytic leukemia in those 
with a specific chromosomal abnormality. However, neutropenia has been reported as 
a side effect. A-1211212 (a close analog of venetoclax) is a BCL-2 selective orally 
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bioavailable inhibitor. Pro-apoptotic A-1211212 reduces the number of neutrophils in 
the circulation of rats without influencing the platelet counts (21).  
BH3 mimetics that antagonize BCL‐2 family proteins were initially developed for the 
treatment of cancer while exhibiting minimal toxicity toward normal cells. Additionally, 
a number of studies demonstrate that the BCL-2 inhibitor ABT-737 is also able to 
enhance apoptosis in pro-inflammatory/autoreactive lymphocytes escaping the 
physiological termination of their life cycle. Thus, ABT-737 is effective in treating animal 
models of autoimmune diseases (22), arthritis (23) and lupus (24). Furthermore, 
expression of the pro-apoptotic BIM, and the extent of its association with BCL-2, 
correlates with in vivo ABT-737 sensitivity (25). Recently, we showed that ABT-737 
limits the persistence of lymphocytes in a mouse model of colitis (26). However, the 
amelioration of colitis was accompanied by lymphopenia.  
In this study, we showed that the expression pattern of BCL-2 family proteins does not 
predict the response to AZA treatment in IBD. Nonetheless, inhibition of BCL-2 initiated 
cell death in CD4+ T cells from patients refractory to AZA. We also found that the BCL-
2 inhibitor A-1211212 effectively diminished accumulated lymphocytes and 
ameliorated colitis without inducing thrombopenia in a murine model of spontaneous 
colitis. Regulating inappropriate survival of autoreactive lymphocytes through the 
inhibition of BCL-2 may provide a new therapeutic strategy in IBD. 
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MATERIALS AND METHODS 
 
Ethical Considerations 
We retrieved data from 48 patients (supplementary table 1) from the SIBDCS, a 
longitudinal, prospective, cohort study of Swiss residents diagnosed with IBD (27) 
approved by the local ethical committees (EK-1316). Animal experiments were 
approved by the Cantonal Comission for Animal Experiments (160/2014).  
 
Next generation sequencing (NGS) 
Blood samples were collected from three patients with sustained remission following 
AZA treatment, and three patients refractory to treatment (supplementary table 1). 
NGS was performed using total RNA that passed Tapestation (Agilent) quality control 
with a RIN > 8.3 (supplementary figure 1). Illumina NGS was performed by the 
Functional Genomics Center Zurich. 
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Isolation and stimulation of human CD4+ T cells from whole blood 
Blood samples were collected before and after treatment with AZA from 27 patients 
with sustained remission following AZA treatment, 21 patients refractory to treatment 
and eight healthy controls without treatment (supplementary table 1). Peripheral blood 
lymphocytes (PBLs) were isolated using Ficoll (Histopaque-1077, 10771-100ML 
Sigma) and resuspended in medium: RPMI-1640 (21875-034, Gibco), 2 mM L-
glutamine, 100 U/ml each of penicillin and streptomycin, 50 mM β-mercaptoethanol 
and 10 % FCS. CD4+ T cells were isolated using the Cell Isolation Kit (130-096-533, 
Miltenyi). For stimulation of CD4+ T cells, a well plate was coated 24 h before the 
experiment with anti-CD3 (0.04 µg/ml, 130-093-387, Miltenyi). CD4+ T cells were 
cultivated (37°C, 5% CO2) during 5 days in media containing IL-2 (40 IU/ml, 130-097-
743, Miltenyi) and anti-CD28 (1 µg/ml, 130-093-375, Miltenyi). ABT-737, -199, -263 (1 
µM each, AbbVie), 6-MP (5 µM, 852678-1G-A, Sigma) or vehicle (DMSO, 41640, 
Sigma) . 
 
Flow cytometry and mass cytometry 
Apoptotic cells were determined by annexin V (ALX-209-252-T100, Enzo Life Science) 
and propidium iodide (PI, P4864, Sigma) staining. Annexin V- / PI- cells were 
considered alive, while early apoptotic cells displayed staining for annexin V but not for 
PI. Late apoptotic cells displayed staining for both, annexin V and PI. Fluorescence 
was measured using a BD FACSCanto II flow cytometer. CD4 was stained with anti-
mouse antibody conjugated with APC-Cy7 (1:200, 552051, BD biosciences), CD8 with 
anti-mouse PerCp Cy5.5 (1:400, 45-0081-80, eBioscience), CD3 with anti-mouse 
antibody APC (1:200, 100236, BioLegend), B220 with anti-mouse Cy7 (1:200, 552772, 
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BD Pharmingen), F4/80 with anti-mouse FITC (1:200, 8940F, Cedarlane) and CD45 
with anti-mouse PB (1:800, 103126, BioLegend). Aqua staining was performed to 
discriminate live and dead cells (1:1000, L34957, Thermo Fisher Scientific).  
Mass cytometry was performed as previously described (26) applying the MaxPar Cell 
Surface Staining Protocol (DVS Sciences, Toronto, Canda) including cell-ID cisplatin 
reagent (201064, Fluidigm) for viability staining, surface antibody cocktail (201306, 
MaxPar Mouse Spleen/Lymph Node Phenotyping Panel Kit) and iridium intercalation 
solution (201192B, Fluidigm). Cells were acquired on the CyTOF 2 instrument 
(Fluidigm). The resulting data were analysed with FlowJo (Flowjo LLC; TreeStar, Inc., 
Ashland, OR, USA) and Cytobank software (Mountain View, CA, USA). 
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qPCR 
Transcriptional expression of murine Bim (#Mm00437796_m1), Bcl-2 
(#Mm00477631_m1*), Bcl-xl (#Mm00437783_m1), Bid (#Mm00432073), Tnf 
(#Mm99999068_m1), Il1β (#Mm01336189_m1), Ifnγ (#Mm00801778_m1), Mcp1 
(Mm00441242_m1) and Tgfβ (Mm01178820_m1) was determined by TaqMan. Actin 
(#4352341E) or glyceraldehyde 3-phosphate dehydrogenase (Gapdh, #4352339E) 
was measured as endogenous control. For human samples, BCL-2 
(#Hs00608023_m1), BCL-XL (#Hs00236329_m1), BMF (Hs00372937_m1) and BIM 
(#Hs01083836_m1) were used. Actin (#4310881E) or Gapdh (#4326317E) was 
measured as endogenous control (Applied Biosystems, respectively). Relative mRNA 
expression was calculated using the Ct method. All samples were analyzed as 
triplicates. 
 
Murine spontaneous colitis model and treatment with BCL-2 inhibitors 
Wild type mice (Jackson), B.6129P2-Il10tm1Cgn/J (Il-10-/-, Jackson) and B.6129P2-
Il10tm1Cgn/J x B6.129-Bcl2l11tm1.1Ast/J (Il-10-/- x Bim-/-) mice  weighing 25-30 g were used. 
A-1211212 (AbbVie, USA) was applied by oral gavage (p.o., 3, 10, 30, 100 mg/kg/day) 
dissolved in 30% polyethylene glycol 400, 60% phosal PG 50 and 10% ethanol. ABT-
737 was injected intra-peritoneally (i.p., 50 mg/kg/day) dissolved in polyethylene glycol, 
Tween 80, dextrose solution and DMSO. Animals were sacrificed on day 14 of 
treatment.  
 
Assessment of colonoscopy and histological score in mice 
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Animals were anesthetized with isoflurane and examined with the Tele Pack Pal 
20043020 (Karl Storz Endoskope, Germany). Mice were scored according to the 
murine endoscopic index of colitis severity (MEICS) as previously described (28). For 
histological analysis, both colon and small bowel were resected and scored as 
described (29, 30).  
 
Isolation and culture of murine primary cells 
For hematological analyses, murine whole blood was collected in EDTA-treated tubes 
(367525, BD vacutainer). Analyses were performed with an ADVIA 2120 flow 
cytometer (Siemens). For mass cytometry of murine PBLs, whole blood was collected 
in EDTA-treated collection tubes. ACK lysing buffer (1,5 M NH4Cl, 100 mM KHCO3, 
10 mM Triplex111, ph 7.2) was used.  
Splenocytes were isolated using the gentleMACS octo dissociator (130-095-937, 
Miltenyi, program m_spleen 03) and gentleMACS C tubes (130-093-237, Miltenyi) 
containing 10 ml ACK lysising buffer. Splenocytes were passed over a 70 μm mesh 
filter. 
For the isolation of lamina propria mononuclear cells (LPMNCs), 10 cm of the small 
bowel was resected and cut in small pieces. 5 ml of a digestive enzyme complex 
containing Collagenase V (C9263-1G, Sigma), Collagenase D (11088882001, Roche), 
Dispase (17105-041, Gibco), DNase (10104159001, Roche) and RPMI medium 
(21875-034, Gibco) with 10% FCS was incubated with the small bowel for 30 min at 
37°C. Suspension was vortexed and passed through a 70 μm mesh filter.  
Murine CD4+CD62L+ cells from spleen were isolated with the T Cell Isolation Kit II (130-
093-227, Miltenyi). For cell culture, a well plate was coated 24 h before the experiment 
with anti-CD3 (2 µg/ml, 130-092-973, Miltenyi). Cells were cultivated in media 
containing IL-2 (4 ng/ml, 402-ML-020/CF, R&D) and anti-CD28 (2 µg/ml, 130-093-182, 
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Miltenyi). ABT-737 (1 µM – 1 x 10-4 µM) and 6-MP (5 µM - 5 x 10-4 µM, final 
concentration each) or vehicle was added for 5 days (37°C, 5% CO2). 
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MPO activity assay 
Both colon and small bowel specimens were homogenized in 50 mM phosphate buffer 
with 0.5% hexadecyltrimethylammonium bromide (H-5882, Sigma) with the 
gentleMACS octo dissociator (130-095-937, Miltenyi, program mpo). After three 
freeze-and-thaw cycles, homogenates were centrifuged for 2 min at maximum speed. 
20 ml of the supernatant were transferred to a 96-well plate in duplicate and mixed with 
280 µl of 0.02% dianisidine (in 50 mM phosphate buffer and 0.0005% H2O2, D-3252, 
Sigma). Absorbance was measured either after 20 min, if samples were from Il-10-/- 
mice or after 60 min, if samples were from WT mice, at 460 nm. Protein concentration 
of the supernatant was determined by the BCA Protein Assay Kit (23252, Thermo 
Fisher Scientific). MPO activity was calculated as mean absorbance (460 
nm)/incubation time/protein content. 
 
Statistical analyses 
All Pairwise Multiple Comparison Procedures (Dunn's Method): Kruskal-Wallis One 
Way Analysis of Variance on Ranks or a non-parametric t test was applied as indicated 
in the figure legends. Differences were considered significant at p < 0.05, highly 
significant at p < 0.01 and p < 0.001.  
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RESULTS 
BCL-2 family expression does not predict AZA treatment response in IBD 
First, we determined whether the mRNA expression pattern of BCL-2 family members 
could be used to predict the response to AZA treatment in IBD patients. For NGS 
analysis, blood samples were collected from patients with sustained remission 
(successfully treated patients, n = 3) or refractory to treatment (primary non-
responders, n = 3, supplementary table 1). Following NGS analysis, we determined 
similar expression of 36 members of the BCL-2-family in patients with remission 
compared to patients refractory to treatment (p > 0.05 each, table 1). To confirm the 
results from NGS, we performed qPCR from 23 patients in remission, 18 refractory 
patients and six healthy controls. For qPCR, blood samples were collected before AZA 
medication therapy and after the outcome. We determined similar expression levels of 
BCL-XL, BCL-2, BMF and BIM in patients before AZA medication therapy with 
remission compared to patients refractory to treatment (supplemetary figures 2 - 5). 
mRNA expression was not correlated with the MTWAI and did not change over time, 
indicating that the expression of BCL-2 family members can not predict AZA treatment 
response in IBD. 
 
BCL-2 family inhibitors, but not 6-MP, induce T cell apoptosis in patients treated 
with AZA 
Next, we determined whether the reduction of lymphocyte counts in IBD patients upon 
AZA treatment is increased by BCL-2 family inhibitors in vitro. Flow cytometry was 
performed to quantify the number of viable and apoptotic CD4+ T cells upon treatment 
with the AZA metabolite 6-MP (5 µM) and the BCL-2 family inhibitor ABT-737 (1 µM) 
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applied for five days. In healthy controls, the relative number of early and late apoptotic 
cells was significantly increased upon 6-MP treatment in vitro compared to vehicle 
(38.1 ± 5.7 % vs. 22.5 ± 1.8 %, $ p < 0.039, figure 1A). The number of apoptotic cells 
was also significantly increased upon ABT-737 treatment (40.5 ± 7.2 %, $ p < 0.028, 
figure 1A) and the combined treatment with 6-MP and ABT-737 compared to vehicle 
(56.3 ± 17.1 %, * p < 0.05, figure 1A). The number of apoptotic CD4+ T cells was also 
significantly increased upon combined treatment compared to 6-MP and ABT-737 
treatment alone ($ p < 0.023 and $ p < 0.032, respectively, figure 1A). 
In contrast, the relative number of early and late apoptotic CD4+ T cells from IBD 
patients treated with AZA remained unchanged upon 6-MP stimulation compared to 
controls (21.1 ± 0.7 % vs. 25.6 ± 7.4 %, figure 1A). The number of apoptotic cells was 
significantly increased upon ABT-737 treatment (35.3 ± 8.1 %, $$ p < 0.040, figure 1A) 
and the combined treatment (36.7 ± 6.3 %, * p < 0.05, figure 1A) compared to vehicle. 
The number of apoptotic CD4+ T cells was significantly increased upon combined 
treatment compared to 6-MP treatment alone ($$ p < 0.045, figure 1A). 
The number of apoptotic CD4+ T cells following 6-MP treatment was significantly 
increased in healthy controls compared to IBD patients treated with AZA (# p = 0.004, 
t-test, figure 1A) and the combined treatment with 6-MP and ABT-737 (# p = 0.011, t-
test, figure 1A). The ratio between apoptotic and non-apoptotic CD4+ T cells in the 
presence of 6-MP or vehicle was significantly decreased in IBD patients receiving AZA 
compared to healthy controls (1.21 ± 0.32 % vs. 1.69 ± 0.28 %, n = 9 and 6, 
respectively, * p < 0.05, supplementary figure 6A).  
Next, we analyzed the effects of these agents on the expression of BCL-2 family 
members. We determined a significant decrease in BCL-XL expression in CD4+ T cells 
from healthy controls following 6-MP stimulation compared to vehicle (0.69 ± 0.12 vs. 
1.00 ± 0.02, n = 3, respectively, p = 0.01, supplementary figure 6B). In CD4+ T cells 
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isolated from IBD patients treated with AZA at time of medical examination, BCL-XL 
gene expression remained unchanged upon 6-MP treatment in vitro after five days 
compared to vehicle (1.00 ± 0.16 vs. 1.00 ± 0.00, n = 8 and 7, respectively, figure 1B). 
BCL-XL was decreased upon treatment with the BCL-2 family inhibitors ABT-737, 
ABT-199 and ABT-263 (0.62.3 ± 0.29, 0.80.3 ± 0.14, n = 8, and 0.62.3 ± 0.25, n = 5; 
respectively, figure 1B) with a significant difference for ABT-737 and ABT-263 (* p < 
0.05 each, figure 1B). BCL-XL was also significantly decreased upon combined 
treatment of 6-MP and ABT-263 (0.59 ± 0.19, n = 5, * p < 0.05, figure 1B). No 
significant difference was determined between ABT-263 and co-treatments. Similarly, 
BCL-2 remained unchanged upon 6-MP stimulation, but was decreased in the 
presence of the BCL-2 inhibitors (supplementary figure 6C, not significant). 
 
BCL-2 family inhibitors initiate cell death in CD4+ T cells from IBD patients 
refractory to AZA 
Next, we determined whether the amount of CD4+ T cells from IBD patients refractory 
to AZA can be further decreased upon combined treatment with 6-MP and the BCL-2 
family inhibitor ABT-737. Blood was drawn from three IBD patients treated with AZA at 
time of medical examination, while a considerable resistance to treatment was 
indicated (supplementary table 1). In CD4+ T cells from three IBD patients refractory to 
AZA, the number of early and late apoptotic cells was increased upon 6-MP treatment 
compared to vehicle (36.6 ± 14.1 % vs. 23.2 ± 12.6 %, n = 3, respectively, figure 2). 
The number of apoptotic CD4+ T cells was further increased upon treatment with ABT-
737 (61.3 ± 21.8 %, n = 3, figure 2) or the combined treatment (68.1 ± 14.6 %, n = 3, 
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p = 0.055, figure 2), suggesting that inhibition of BCL-2 initiated cell death in CD4+ T 
cells from patients refractory to AZA.  
Additionally, we determined whether cell survival can be also decreased upon 
combined treatment in murine CD4+CD62L+ splenocytes. Cell death also increased in 
a dose-dependent manner in splenocytes upon 6-MP treatment (supplementary figure 
7A). As 6-MP was less effective in cells isolated from Balb/C mice compared to B6 
mice, we determined Bcl-XL in CD4+CD62L+ splenocytes and found increased 
expression in Balb/C mice compared to B6 mice (p = 0.057, t-test, supplementary 
figure 7B). Cells isolated from Balb/C mice and B6 mice were used for combined 
treatment experiments. In Balb/C, apoptosis in splenocytes was further increased upon 
the combined treatment with 6-MP and ABT-737 compared to treatment with a single 
compound or vehicle (supplementary figure 7C), confirming the results obtained with 
human T cells. In B6, apoptosis in splenocytes upon 6-MP or combined treatment was 
significantly increased compared to vehicle (* p< 0.05, SEM, supplementary figure 7C). 
 
A-1211212 is detected in blood and intestine following oral gavage in mice 
 
The broad range BCL-2 inhibitor ABT-737, which inhibits BCL-2, BCL-XL and BCL-ω, 
triggers undesirable side effects, including lymphopenia. To reduce adverse side 
effects, we determined the impact of the BCL-2 specific inhibitor A-1211212 on 
mucosal inflammation using the Il-10-/- mouse model of spontaneous colitis. A 
calculated dose of 3, 10, 30 and 100 mg/kg/day was applied by oral gavage for 14 
days. Peripheral blood, intestinal epithelial cells (IECs) and whole colon tissue of mice 
were harvested to confirm the accumulation of A-1211212 in these samples. Following 
14 days of treatment, mass spectrometric (MS) analysis detected A-1211212 in sera 
in a dose-dependent manner (0.01 ± 0.00, 0.29 ± 0.09, 0.51 ± 0.24, 0.81 ± 0.13, 
1.69 ± 0.01 μg/mL for vehicle, 3, 10, 30 and 100 mg/kg/day, n = 2, respectively). MS 
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analysis also detected A-1211212 in intestinal mucosa in a dose-dependent manner 
(1.7, 0.3, 20.4, 42.1 μg/g for vehicle, 3, 30 and 100 mg/kg/day, n = 1, respectively). 
Less A-1211212 was detected in IECs (< 0.1, 0.3, 1.1, 1.2 μg/g for vehicle, 3, 10 and 
30 mg/kg/day, n = 1, respectively).  
 
A-1211212 ameliorates spontaneous colitis  
Next, we determined the influence of A-1211212 and the broad range inhibitor ABT-
737 on mucosal inflammation. Externally, Il-10-/- mice showed a clearly visible rectal 
prolapse at the beginning of the experiment that was associated with cryptitis and a 
massive lymphocyte influx into the intestinal mucosa as determined by H&E staining 
(supplementary figure 8). Macroscopic mucosal damage was assessed by mini-
endoscopy. Mice received either A-1211212 or vehicle, or ABT-737 or vehicle over 14 
days. Wild type mice showed unchanged MEICS regardless of treatment (figure 3B). 
Il-10-/- mice receiving vehicle displayed an opaque mucosa and altered vascular 
pattern on day 14 (MEICS 4.6 ± 0.7 and 6.0 ± 2.12, A-1211212 and ABT-737, n = 8 
and 6 respectively, figure 3B). Prominent thickening of the colon and thin feces were 
observed and the diseased regions presented mucosal bleeding frequently. During 
treatment with both A-1211212 and ABT-737, inflammation was ameliorated compared 
to vehicle-receiving mice. Il-10-/- mice treated with both A-1211212 and ABT-737 had 
a transparent mucosa with a regular vascular pattern and solid feces were visible 
(MEICS 1.3 ± 0.6 and 3.7 ± 1.3, for 10mg/kg/day A-1211212 and ABT-737, n = 5 and 
6, respectively, figure 3B).  
Microscopic mucosal damage was assessed by histological score. Mice received 
either A-1211212 (3, 10, 30, 100 mg/kg/day) or vehicle, or ABT-737 (50 mg/kg/day), 
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or vehicle over 14 days. Wild type mice showed unchanged histological score 
regardless of treatment (figure 4B). The histological score of Il-10-/- mice upon 
treatment with A-1211212 or ABT-737 was significantly lower compared to vehicle-
treated mice in small bowel (2.17 ± 0.76 and 3.84 ± 0.28, for 30 mg/kg/day A-1211212 
and vehicle, n=7 and 10, respectively, *** p < 0.001, figure 4B) and colon (2.36 ± 0.48 
and 4.17 ± 0.54, for 30 mg/kg/day A-1211212 and vehicle, n=7 and 10, respectively ** 
p < 0.01, supplementary figure 9). Il-10-/- mice also presented less lymphocyte influx 
into the thickened lamina propria (white arrows, figure 4A). In summary, BCL-2 
inhibitors positively altered the colonic mucosa at both macroscopic and microscopic 
level in the Il-10-/- model of spontaneous colitis. 
To quantify the formation of reactive oxygen species, we performed MPO activity 
assay. In contrast to WT mice, Il10-/- mice showed considerably enhanced MPO activity 
in both small bowel and colon (figure 5A and B). Compared to vehicle-treated mice, A-
1211212 treatment decreased MPO activity in a dose-dependent manner in both small 
bowel and colon in Il-10-/- mice (47.08 ± 28.52 and 162.56 ± 141.25, for 100 mg/kg/day 
A-1211212 and vehicle, n=8 and 8, respectively, * p < 0.05, figure 5A). 
We determined gene expression of pro-inflammatory cytokines in whole mucosal 
tissue in WT and Il-10-/- mice upon A-1211212 treatment. In WT, Tnf, Il1β, Ifnγ, Mcp1 
and Tgfβ gene expression was not regulated in a dose-dependent manner (not shown). 
Next, we determined whether the ameliorated colitis in Il-10-/- mice upon A-1211212 
was associated with a decrease in pro-inflammatory cytokines. At day 14, Tnf gene 
expression was significantly decreased upon administration of 30 mg/kg/day A-
1211212 compared to vehicle (0.46 ± 0.21 vs. 1.00 ± 0.24, n=7 and 8, respectively, * 
p < 0.05, figure 6A). Il1β was significantly decreased upon treatment with 10 mg/kg/day 
A-1211212 compared to vehicle (0.41 ± 0.23 vs. 1.00 ± 0.30, n=7 and 8, respectively, 
* p < 0.05, figure 6A). Ifnγ was significantly decreased upon treatment with 100 
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mg/kg/day A-1211212 compared to vehicle (0.57 ± 0.19 vs. 1.00 ± 0.15, n=5 and 8, 
respectively, * p < 0.05, figure 6A). Mcp1 was significantly decreased upon treatment 
with 100 mg/kg/day A-1211212 compared to vehicle (0.43 ± 0.25 vs. 1.00 ± 0.63, n=7 
and 10, respectively, * p < 0.05, figure 6A). In contrast, Tgfβ increased in a dose-
dependent manner upon treatment with A-1211212 compared to vehicle (2.86 ± 2.92 
vs. 1.00 ± 0.29, for 100 mg/kg/day A-1211212 and vehicle, n=9 and 10, respectively, 
figure 6B).  
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A-1211212 shows platelet-sparing features, but shifts lymphocyte populations 
in vivo  
Hematological analyses were performed in wild type mice and in the Il-10-/- model of 
spontaneous colitis to determine whether the increase in number of apoptotic cells 
upon A-1211212 treatment was associated with a shift in cell populations. Erythrocyte 
fraction was not affected in wild type mice and Il-10-/- mice after 14 days of p.o. gavage 
of A-1211212 and i.p. injection of ABT-737, when compared to vehicle-receiving 
controls (table 2). The platelet fraction remained unchanged upon A-1211212 
treatment, but was significantly decreased following ABT-737 administration when 
compared to vehicle-receiving controls (** p = 0.005, t-test, table 2). The lymphocyte 
fraction was significantly decreased in wild type and Il-10-/- mice after 14 daily 
administration of 100 mg/kg/d A-1211212 or 50 mg/kg ABT-737, when compared to 
vehicle-receiving controls (* p < 0.05, ANOVA, table 2). The absolute number of 
lymphocytes was significantly decreased in wild type mice upon administration of 100 
mg/kg/d A-1211212 compared to controls (0.39 ± 0.04 x 103 cells/μL, n = 5 vs. 
2.23 ± 0.80 x 103 cells/μL, n = 5, respectively, t-test, ** p = 0.008). The absolute 
number of lymphocytes was also significantly decreased in Il-10-/- mice upon 
administration of 100 mg/kg/d A-1211212 compared to controls (0.41 ± 0.31 x 103 
cells/μL, n = 6 vs. 1.80 ± 0.99 x 103 cells/μL, n = 8, respectively, t-test, ** p = 0.003) 
and upon administration of 50 mg/kg/d ABT-737 compared to controls (0.49 ± 0.08 x 
103 cells/μL, n = 3 vs. 1.17 ± 0.40 x 103 cells/μL, n = 3, respectively, t-test, * p < 0.05). 
As inhibition of BCL-2 by ABT-737 is mediated by displacing the pro-apoptotic factor 
BIM, we also applied ABT-737 to Il-10-/- x Bim-/- mice. The fraction of lymphocytes in 
these mice was unaltered upon ABT-737 treatment (table 2) and the absolute number 
of lymphocytes remained unchanged, confirming that BIM is required for the protective 
effect of ABT-737.  
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The monocyte fraction was decreased in Il-10-/- mice after 14 daily administration of A-
1211212 or ABT-737, when compared to vehicle-receiving controls (table 2). The 
granulocyte fraction was increased in Il-10-/- mice after 14 daily administration of A-
1211212, and was significantly increased upon ABT-737 treatment (** p = 0.002, t-test, 
table 2). In Il-10-/- x Bim-/- mice, the fraction of granulocytes was unaltered upon ABT-
737 administration and the absolute number of granulocytes remained unchanged.  
 
The BCL-2 inhibitor significantly decreases the amount of CD8+ T cells  
CD4+ and CD8+ splenocytes from wild type and colitic Il-10-/- mice were analyzed by 
flow cytometry. In WT mice, a significant decrease in CD8+ T cells following treatment 
with A-1211212 compared to vehicle-receiving controls was determined (6.5 ± 1.9 % 
vs. 14.5 ± 4.3 %, for 30 mg/kg/day A-1211212 and vehicle, n=4 and 7, respectively, ** 
p < 0.01, ANOVA, figure 7). Similarily to the results obtained from WT mice, we 
determined a significant decrease in CD8+ T cells following treatment with A-1211212 
compared to vehicle-receiving controls (4.0 ± 1.3 % vs. 11.7 ± 3.0 %, for 30 mg/kg/day 
A-1211212 and vehicle, n=5 and 5, respectively, ** p < 0.01, ANOVA, figure 7).  
Additionally, we determined the CD8+ T cell population in PBL in an individual 
measurement by mass cytometry. Confirmative to flow cytometry, the proportion of 
CD8+ T cells was decreased upon A-1211212 (supplementary figure 10A and B). The 
proportion of central memory T cells was decreased upon A-1211212 treatment 
compared to vehicle-receiving controls (CD45+, CD19-, B220-,TCRβ+, CD3+, CD8+, 
CD44+ CD62L+, supplementary figure 10C).  
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DISCUSSION 
In accordance with previous reports (11), our results show that the expression pattern 
of BCL-2 family members in CD4+ T cells is changed upon treatment with the AZA 
metabolite 6-MP. Nonetheless, transcriptome analysis using NGS indicates that the 
response to AZA treatment in IBD patients cannot be estimated from mRNA expression 
levels of BCL-2 family members. Although refractory patients and patients in remission 
were carefully chosen for this study, treatment duration, medication therapy prior to the 
study, and co-medication during AZA treatment was variable for the benefit of patients. 
However, given the highly similar expression levels of BCL-2 family members in both 
groups over time, a predictive value seems unlikely. 
6-MP therapy is unable to rescue IBD patients resistant to AZA treatment, evidencing 
a pressing need for alternative therapies limiting lymphocyte lifespan in these patients. 
We could confirm previous results that 6-MP is reducing the number of CD4+ 
lymphocytes in vitro in healthy controls not receiving AZA prior to blood collection. In 
contrast, reduction is limited in IBD patients already receiving AZA. It is well established 
that dysregulated apoptosis of activated lymphocytes driven by increased anti-
apoptotic BCL-2 and BCL-XL contributes to the pathogenesis of IBD (1, 4, 6, 31, 32). 
Consequently, our results show that the BCL-2 inhibitors ABT-737, ABT-199 and ABT-
263 limit the persistence of human CD4+ lymphocytes in IBD patients receiving AZA 
prior to blood collection. Further, ABT-737 was shown to limit the persistence of human 
CD4+ lymphocytes in IBD patients refractory to AZA treatment. Similar results were 
obtained in previous studies using different BCL-2 inhibitors in various inflammatory 
conditions characterized by the uncontrolled proliferation of lymphocytes, BCL-2 
inhibitors were efficacious in reducing accumulated lymphocytes in murine models of 
autoimmune diseases (22), arthritis (23) and lupus (24), and suppressed allogeneic T- 
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and B-cell responses after skin transplantation in vitro and in vivo (33). A recent report 
assessing the effects of BCL-2 inhibitors in steroid-insensitive airway inflammation 
showed that BCL-2 inhibitors ameliorate corticosteroid-resistant airway inflammation 
(34). Increased BCL-2 was found to be responsible for the persistence of granulocytes 
in bronchoalveolar lavage fluid after allergic challenge. Notably, BCL-2 inhibitors were 
more efficient than steroids in inducing granulocyte apoptosis in cells from patients with 
severe asthma (34). 
In our previous work, we showed that the broad range BCL-2 inhibitor ABT-737 
ameliorates inflammation in both the murine model of DSS-induced acute colitis and 
the Il-10-/- model of spontaneous colitis (26). However, this effect on inflammation was 
accompanied by lymphopenia due to ABT-737-mediated inhibition of BCL-2, BCL-XL 
and BCL-ω (17, 18). Inhibition of BCL-XL may be responsible for the reduction of 
platelet lifespan and the observed thrombocytopenia. As a consequence, in the 
present study we administered the newly developed BCL-2 selective pro-apoptotic 
compound A-1211212 to the Il-10-/- model of spontaneous colitis to avoid adverse side 
effects. A-1211212 is a BH3-only mimetic that shows a potent action against various 
transformed cells, while exhibiting minimal toxicity toward normal cells. Similarly to 
ABT-737, the specific BCL-2 inhibitor A-1211212 was detected in peripheral blood, 
colon tissue and IECs following oral gavage. In contrast to ABT-737, we did not 
observe thrombocytopenia upon A-1211212 treatment. However, similarly to ABT-737, 
A-1211212 diminished proportions of CD8+ and central memory T cells accompanied 
by a decrease in Tnf, Ifnγ, Mcp1 and Il1β gene expression in A-1211212-treated mice. 
Naïve T cells survival is mediated by MCL-1 and BCL-2 (35). Consequently, CD4+ 
naïve T cells escape apoptosis in the presence of A-1211212, which is not inhibiting 
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MCL-1. A-1211212 positively alters the colonic mucosa at both macroscopic and 
microscopic level, while ameliorating intestinal inflammation in the Il-10-/- model of 
spontaneous colitis, as shown by MEICS and histological score. Inactivation of BCL-2 
is key for BIM to directly bind to pro-apoptotic BAX and BAK in order to initiate 
apoptosis (36). As inhibition of BCL-2 is also mediated by BIM, we administered A-
1211212 to Il-10-/- x Bim-/- mice upon spontaneous colitis. Interestingly, colitis in mice 
lacking Bim was not ameliorated by A-1211212 treatment confirming the crucial role of 
this factor in the pharmacological inhibition of BCL-2. 
Adjusting the balance between activated and regulatory lymphocyte populations 
through the inhibition of autoreactive lymphocytes may represent a promising novel 
therapeutic strategy for CD patients. Our results point to a potential use of the BCL-2 
selective, platelet-sparing inhibitor A-1211212 as a new therapeutic drug for the 
treatment of intestinal inflammation, particularly for IBD patients refractory to AZA 
treatment. 
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Titles and legends to figures 
 
Figure 1: 6-MP-mediated apoptosis is abolished in CD4+ T cells from IBD patients 
upon AZA at time of medical examination. Flow cytometry and qPCR. (A) 
PI/annexin V staining of human CD4+ T cells from healthy controls and IBD patients 
upon AZA at time of medical examination. ANOVA on Ranks, All Pairwise Multiple 
Comparison Procedures (Dunn's Method), n as indicated, error bars = SD, * p < 0.05. 
$ = Statistics considering healthy controls. $$ = Statistics considering patients. # = t-
test, normality test (Shapiro Wilk) and equal variance test passed. (B) BCL-XL qPCR. 
ANOVA, All Pairwise Multiple Comparison Procedures (Dunn's Method), error bars = 
SD, * p < 0.05. 
 
Figure 2: Inhibition of BCL-2 initiates cell death in CD4+ T cells from IBD patients 
refractory to AZA. Flow cytometry from three IBD patients upon AZA treatment at 
time of medical examination, while a considerable deterioration to treatment was 
indicated. 
 
Figure 3: A-1211212 and ABT-737 ameliorate colitis in Il-10-/- mice. (A) 
Miniendoscopy was performed with a limited number of mice: 23 WT mice and 38 Il-
10-/- mice, (B) MEICS upon A-1211212 or ABT-737 treatment in WT mice and Il-10-/- 
mice suffering from spontaneous colitis following 14 days of treatment, n as indicated, 
error bars = SD. One Way ANOVA, All Pairwise Multiple Comparison Procedures 
(Holm-Sidak Method) for A-1211212 and non-parametric t test for ABT-737, * p < 0.05, 
** p < 0.01, *** p < 0.001. 
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Figure 4: A-1211212 and ABT-737 ameliorate colitis in Il-10-/- mice. (A) H&E, (B) 
histological score from small bowel of 23 WT mice and 48 Il-10-/- mice suffering from 
spontaneous colitis following 14 days of treatment with A-1211212. Arrows indicate 
influx of lymphocytes, error bars = SD. One Way ANOVA, All Pairwise Multiple 
Comparison Procedures (Holm-Sidak Method) for A-1211212 and non-parametric t 
test for ABT-737, * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Figure 5: A-1211212 decreases MPO in Il-10-/- mice in a dose dependent manner. 
MPO assay using small bowel (A) and colon tissue samples (B) from 23 WT mice and 
32 Il-10-/- mice suffering from spontaneous colitis following 14 days of treatment with 
A-1211212, error bars = SD. One Way ANOVA, All Pairwise Multiple Comparison 
Procedures (Dunn’s Method), * p < 0.05. 
 
Figure 6: A-1211212 decreases inflammatory cytokine mRNA expression in Il-10-
/- mice. qPCR from small bowel. (A) Tnf, Il1β, Ifnγ and Mcp1, (B) Tgfβ mRNA 
expression in Il-10-/- mice suffering from spontaneous colitis following 14 days of 
treatment with A-1211212, n as indicated, error bars = SD. One Way ANOVA, All 
Pairwise Multiple Comparison Procedures (Dunn’s Method) for Tnf and (Holm-Sidak 
Method) for Il1β, Ifnγ and Mcp1, * p < 0.05. 
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Figure 7: A-1211212 decreases CD8+ T cell population in splenocytes in WT and 
Il-10-/- mice. Flow cytometry analysis of 23 WT and 26 Il-10-/- mice suffering from 
spontaneous colitis following 14 days of treatment with A-121121. (A) Representative 
images of flow cytometry analysis, n = total 49. Doublets discrimination performed, 
viable and dead cells included. Cells shown were gated to CD45+ and CD8+ or CD4+ 
splenocytes cells, (B) Dose-dependent decrease of CD8+ splenocytes in WT and Il10−/− 
mice upon A-1211212 treatment compared to vehicle as determined by flow cytometry, 
error bars = SD. One Way ANOVA, All Pairwise Multiple Comparison Procedures 
(Dunn’s Method), * p < 0.05, ** p < 0.01, *** p < 0.001.  
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Table 1 
 
Gene name primary 
non-response 
successful P value 
BAD 174 ± 18 162 ± 11 P = 0.406 
BAK1 487 ± 150 526 ± 50 P = 0.346 
BAX 996 ± 76 954 ± 17 P = 0.396 
BCL10 1213 ± 669 701 ± 185 P = 0.270 
BCL11A 155 ± 86 187 ± 50 P = 0.612 
BCL11B 1026 ± 562 2199 ± 1612 P = 0.300 
BCL11B 1026 ± 562 2199 ± 1612 P = 0.300 
BCL2 1164 ± 448 1800 ± 504 P = 0.178 
BCL2A1 6226 ± 4276 4750 ± 2766 P = 0.642 
BCL2L10 0.00 ± 0.00 0.80 ± 0.71 P = 0.121 
BCL2L12 80 ± 27 117 ± 23 P = 0.138 
BCL2L13 822 ± 38 864 ± 42 P = 0.271 
BCL2L14 3.99 ± 0.66 3.96 ± 3.47 P = 0.991 
BCL2L15 27 ± 4 27 ± 8 P = 0.895 
BCL3 3775 ± 2072 2452 ± 466 P = 0.341 
BCL6 43067 ± 28035 21750 ± 13060 P = 0.299 
BCL6B 0.36 ± 0.62 1.53 ± 1.62 P = 0.309 
BCL7A 85 ± 65 98 ± 72 P = 0.830 
BCL7B 683 ± 80 675 ± 107 P = 0.923 
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BCL7C 213 ± 67 252 ± 54 P = 0.482 
BCL9 341 ± 113 355 ± 39 P = 0.854 
BCL9L 2224 ± 1137 2981 ± 1104 P = 0.455 
BCLAF1 4273 ± 755 5018 ± 601 P = 0.252 
BCLW, BCL2L2 236 ± 114 263 ± 19 P = 0.700 
BCLXL, BCL2L1 1293 ± 520 783 ± 70 P = 0.167 
BID 2722 ± 966 2601 ± 800 P = 0.875 
BIK 25 ± 5 16 ± 6 P = 0.131 
BIM, BCL2L11 2045 ± 295 1771 ± 703 P = 0.567 
BMF 705 ± 351 1090 ± 121 P = 0.147 
BOK 7.72 ± 7.29 1.56 ± 2.14 P = 0.233 
MCL1 81490 ± 38202 55673 ± 20213 P = 0.359 
NOXA1 73 ± 44 131 ± 52 P = 0.214 
PUMA 508 ± 118 559 ± 270 P = 0.780 
TMBIM1 4382 ± 981 3516 ± 837 P = 0.310 
TMBIM4 3078 ± 1129 2224 ± 812 P = 0.347 
TMBIM6 19610 ± 6185 15273 ± 3684 P = 0.356 
 
Table 1: Results from NGS for the BCL-2-family in alphabetical order. Normalized counts ± SD for IBD patients with a primary non-
response to AZA (column two) and patients successfully treated with AZA (third column). P values (p > 0.05 each, t-test) 
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Table 2 
 wild type IL-10-/- IL-10-/- x BIM-/- 
A-1211212 A-1211212 ABT-737 
mg / kg / day vehicle 3 10 30 100 vehicle 3 10 30 100 vehicle 50 vehicle 50 
n = 5 3 5 5 5 8 5 7 5 6 3 3 5 4 
erythrocytes 
(1012/L) 
9.48 
± 0.43 
8.61 
± 0.32 
9.15 
± 0.59 
9.02 
± 0.55 
9.29 
± 0.25 
9.31 
± 0.54 
9.92 
± 0.42 
9.49 
± 
1.07 
9.37 
± 0.80 
8.95 
± 0.34 
8.47 
± 0.96 
8.78 
± 0.43 
7.38 
± 4.04 
6.61 
± 3.65 
 
platelets 
(103/µL) 
1205 
± 251 
1194 
± 88 
1180 
± 462 
920 
± 280 
1120 
± 350 
1201 
± 268 
1279 
± 363 
1260 
± 282 
1075 
± 317 
1209 
± 379 
1332 
± 170 
733 
± 73 
n.d. n.d. 
     ** 
lymphocytes 
(%) 
75.3 
± 9.1 
57.3 
± 24.8 
57.7 
± 9.8 
35.1 
± 10.4 
31.6 
± 8.5 
59.5 
± 8.7 
52.5 
± 17.2 
37.1 
± 9.6 
42.5 
± 8.0 
31.8 
± 12.6 
56.43 
± 6.5 
30.07 
± 3.0 
81.18 
± 7.5 
78.80 
± 10.1 
 * * * 
monocytes 
(%) 
0.72 
± 0.47 
1.13 
± 0.38 
1.14 
±0.29 
1.04 
± 0.43 
1.24 
± 0.47 
1.66 
± 1.61 
1.25 
± 0.45 
1.12 
±0.46 
1.30 
± 0.22 
1.16 
± 0.27 
1.83 
± 0.42 
1.23 
± 0.55 
8.18 
± 6.92 
13.28 
± 8.71 
    
granulocytes 
(%) 
23.4 
± 9.1 
40.9 
± 25.0 
40.4 
± 9.4 
63.4 
± 10.3 
65.8 
± 9.3 
39.1 
± 8.7 
43.8 
± 18.9 
59.1 
±10.4 
54.5 
± 7.2 
56.7 
± 20.6 
39.47 
± 5.90 
67.30 
± 3.18 
5.16 
± 4.68 
3.20 
± 1.20 
 *  ** 
neutrophiles 
(%) 
20.7 
± 8.7 
25.7 
± 12.2 
30.1 
± 5.3 
53.6 
± 11.6 
55.7 
± 12.8 
38.5 
± 7.8 
40.7 
±19.7 
48.2 
± 6.0 
47.2 
± 5.1 
44.2 
± 15.5 
34.40 
± 5.37 
58.27 
± 0.85 
4.36 
± 4.70 
2.45 
± 0.96 
*      *   
 
Table 2: Hematological analyses. PBLs from wild type mice and mice from the Il10-/- and Il10-/- x Bim-/- model of spontaneous colitis. The platelets fraction 
remained unchanged upon A-1211212, but was significantly decreased upon ABT-737, when compared to vehicle-receiving controls, n as indicated, error 
bars = SD. Statistics for mice upon A-1211212 was performed using ANOVA on ranks (Holm-Sidak method). Statistics for mice upon ABT-737 was performed 
using t-test, * p < 0.05, ** p < 0.01. Black arrows with a star indicate a significant difference, grey arrows indicate a trend.  
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Supplementary table 1 
ID Gender 
(male, 
female) 
Age 
(years) 
Duration of 
disease at 
sampling 
(years) 
Clinical disease 
activity at 
sampling (active, 
quiescent, 
remission, 
refractory) 
AZA / 6 MP Additional 
medication 
(per day, unless 
otherwise 
described) 
MTWSI / 
Montreal 
classific
ation 
Physical complaints Used for 
1 male 39 8 sustained 
remission, colitis 
ulcerosa 
Azathioprine, 
175 
Oral 5-ASA 
Topical 5-ASA 
Systemic steroids 
VitD 
Prednison 5 mg 
 
- Prior to medication: Abdominal pain 
(severe) 
Stool is diluted and/or blood contents 
Post medication: No abdominal pain 
No evidence of any relapse 
NGS 
qPCR 
2 male 41 10 sustained 
remission, colitis 
ulcerosa 
Azathioprine, 
175 
5-ASA 500 
Proton pump 
inhibitor 
Non-steroidal anti-
inflammatory drugs 
- Prior to medication: Abdominal pain  
Stool with blood contents 
Multiple stool (10 x / day) 
Post medication: No abdominal pain 
No evidence of any relapse 
NGS 
qPCR 
3 female 31 10 sustained 
remission, colitis 
ulcerosa 
PuriNethol 
50 mg 
Oral 5-ASA, 3000 
5-ASA, 2000 
- Prior to medication: Abdominal pain 
(severe) due to quit smoking 
Stool is diluted and/or blood contents 
Post medication: No abdominal pain 
No evidence of any relapse 
NGS 
qPCR 
4 female 39 13 refractory to 
treatment, colitis 
ulcerosa 
Imurek 
150 mg 
Systemic steroids 
5-ASA 
- Abdominal pain (mild) 
Stool is diluted and/or blood contents 
NGS 
qPCR 
5 male 28 2 refractory to 
treatment, colitis 
ulcerosa 
PuriNethol 
50 mg 
Ursofalk 500 mg 
Budenofalk 3 mg 
Saloflak 1.5 g 
- Stool irregularities 
Abdominal pain (mild) 
 
NGS 
qPCR 
6 male 45 2 refractory to 
treatment, colitis 
ulcerosa 
Imurek 
150 mg 
Prednison 20 mg 
Calcimagon 
Salofalk 3 g 
Salofalk supp. 
Salofalk foam 
Scheriproct 
ointment 
- Multiple stool (10 x / day) 
Stool is diluted and/or blood contents 
Abdominal pain (mild) 
Perianal pain 
Episodes of incontinence 
NGS 
qPCR 
7 female 35 NA healthy control no no mediactaion 0 no physical complaints PI / annexin V 
qPCR 
8 male 45 NA healthy control no no mediactaion 0 no physical complaints PI / annexin V 
qPCR 
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9 male 31 NA healthy control no no mediactaion 0 no physical complaints PI / annexin V 
qPCR 
10 female 28 NA healthy control no no mediactaion 0 no physical complaints PI / annexin V 
qPCR 
11 female 44 NA healthy control no no mediactaion 0 no physical complaints PI / annexin V 
qPCR 
12 male 26 NA healthy control no no mediactaion 0 no physical complaints PI / annexin V 
qPCR 
13 male 45 NA healthy control no no mediactaion 0 no physical complaints PI / annexin V 
qPCR 
14 male 28 NA healthy control no no mediactaion 0 no physical complaints PI / annexin V 
qPCR 
15 female 41 6 sustained 
remission, colitis 
ulcerosa 
Azathioprine, 
150 
Oral 5-ASA, 8cp/j, 
Infliximab, 12, 
Topical 5-ASA, 
2000 
6 ing PI / annexin V  
qPCR 
16 female 44 9 sustained 
remission, colitis 
ulcerosa 
Azathioprine 
shortly 
before 
sampling 
Systemic steroids, 
40 
0 ing qPCR 
17 male 35 2 sustained 
remission, colitis 
ulcerosa 
Azathioprine 
shortly 
before 
sampling 
Oral 5-ASA 3 ing qPCR 
18 female 34 22 sustained 
remission, colitis 
ulcerosa 
Azathioprine 
shortly 
before 
sampling 
Oral 5-ASA, 3000, 
Calcium, VitD 
1 ing qPCR 
19 female 35 23 sustained 
remission, colitis 
ulcerosa 
Azathioprine 
shortly 
before 
sampling 
Oral 5-ASA, 3000, 
Calcium, VitD 
1 ing qPCR 
20 female 39 27 sustained 
remission, colitis 
ulcerosa 
Azathioprine 
shortly 
before 
sampling 
Topical 5-ASA, 
1500, Oral 5-ASA, 
1500 
1 ing qPCR 
21 
male 
 49 24 
sustained 
remission, colitis 
ulcerosa 
Azathioprine, 
150 - 
1 
 
ing PI / annexin V 
qPCR 
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22 
male 
 
51 
 
26 
 
sustained 
remission, colitis 
ulcerosa 
Azathioprine, 
150 - 
0 
 
ing PI / annexin V 
qPCR 
23 male 
 
 
52 
 
 
27 
 
 
sustained 
remission, colitis 
ulcerosa 
Azathioprine, 
150 mg 
 
Systemic steroids, 
30, Topical 5-ASA, 
1000 
8 
 
 
ing PI / annexin V 
qPCR 
24 male 
 
 
 
57 
 
 
 
31 
 
 
 
sustained 
remission, colitis 
ulcerosa 
Azathioprine 
shortly 
before 
sampling 
Cyclosporine, 100 
 
 
 
0 
 
 
 
ing qPCR 
25 female 
 
 
 
31 
 
 
 
5 
 
 
 
sustained 
remission, colitis 
ulcerosa 
Azathioprine 
shortly 
before 
sampling 
Systemic steroids, 
Oral 5-ASA 
 
 
2 
 
 
 
ing qPCR 
26 male 
 
 
 
29 
 
 
 
1 
 
 
 
sustained 
remission, colitis 
ulcerosa 
Azathioprine 
shortly 
before 
sampling 
Systemic steroids, 
Magnes, Calcium, 
VitD 
 
18 
 
 
 
ing qPCR 
27 
male 
 
30 
 
2 
 
sustained 
remission, colitis 
ulcerosa 
Azathioprine, 
100 
- 
 
1 
 
ing PI / annexin V 
qPCR 
28 male 40 9 sustained 
remission, colitis 
ulcerosa 
AZA 
175 mg 
Systemic steroids, 
Oral 5-ASA 
VitD 
- Prior to medication: Abdominal pain 
(severe) 
Stool is diluted and/or blood contents 
Post medication: No abdominal pain 
No evidence of any relapse 
PI / annexin V 
qPCR 
29 female 61 27 sustained 
remission, colitis 
ulcerosa 
PuriNethol Systemic steroids, 
Oral 5-ASA 
Saloflak 
Infliximab 
- Prior to medication: Abdominal pain 
(severe) 
Stool is diluted and/or blood contents 
Post medication: No abdominal pain 
No evidence of any relapse 
qPCR 
30 male 42 11 sustained 
remission, colitis 
ulcerosa 
Imurek 
125 mg 
Quetiapin XR 
Citalopram 20 mg 
Etodolac 600 mg 
Novalgin 
Dafalgan 3g / day 
Mesalazin 500 mg 
Valaciclovir 
Antabus 3 x / week 
Vitamin D 1 x / 
month 
- Prior to medication: abdominal pain 
(moderate) 
Post medication: Multiple stool (10 x / 
day) but no abdominal pain 
 
 
qPCR 
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31 
male 31 11 
sustained 
remission, Crohn’s 
disease 
AZA 
100 mg 
Budenosid oral 3mg 
A: 1, L: 4, 
B: 4 
Prior to medication: Abdominal pain 
Stool with blood contents  
Post medication: No evidence of any 
relapse 
Extraintestinal: arthritis 
 
qPCR 
32 female 40 22 sustained 
remission, colitis 
ulcerosa 
AZA 
100 mg 
5ASA oral 4.5 g 
vitamin D 
corticosteroids 
Scheriproct sopp. 
1 
Prior to medication: Abdominal pain 
Stool is diluted and/or blood contents 
Post medication: Multiple stool (1 – 2 x / 
day) 
 
qPCR 
33 female 32 4 sustained 
remission, Crohn’s 
disease 
PuriNethol 
50 mg 
Salazopyrin 500 mg - Prior to medication: Abdominal pain 
Stool is diluted and/or blood contents 
Post medication: Multiple stool (5 – 6 x / 
day) but no abdominal pain 
Augmented arthralgia and cramps 
Rhinosinusitis 
 
qPCR 
34 female 60 > 2 sustained 
remission, Crohn’s 
disease 
Imurek 
shortly 
before 
sampling 
no - Prior to medication: Abdominal pain 
Perianal fistula 
Post medication: No evidence of any 
relapse 
qPCR 
35 female 42 27 sustained 
remission, colitis 
ulcerosa 
Imurek 
150 mg 
Budenofalk 3 mg 
Saloflak 1.5 g 
 
- Prior to medication: Abdominal pain  
Post medication: No evidence of any 
relapse 
No abdominal pain 
 
qPCR 
36 male 29 2 sustained 
remission, colitis 
ulcerosa 
Purinethol 
50 mg 
Entyvio 
Ursofalk 500 mg 
Budenofalk 3 mg 
Saloflak 1.5 g 
Vitamin D 
- Prior to medication: Abdominal pain  
Stool is diluted 
Post medication: Stool irregularities 
qPCR 
37 female 26 14 sustained 
remission, Crohn’s 
disease 
Purinethol 
50 mg 
Vi-De 3 - Prior to medication: Abdominal pain 
(moderate) 
Stool (3 – 4 x / day) 
Stool is diluted 
Post medication: Infrequent constipation 
No evidence of any relapse 
qPCR 
38 female 38 13 sustained 
remission, colitis 
ulcerosa 
Purinethol 
50 mg 
every other 
day 
5ASA oral 1.5 g 
5ASA rectal every 
third day 
 
1 Prior to medication: Abdominal pain 
(severe) 
Stool is diluted and/or blood contents 
Post medication: Stool (1 – 2 x / day) 
No abdominal pain 
No evidence of any relapse 
qPCR 
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39 
male 62 3 
refractory to 
treatment Azathioprine Systemic steroids 6 
ing qPCR 
40 
male 64 6 
refractory to 
treatment Azathioprine 
Systemic steroids, 
10, Calcium VitD 8 
ing qPCR 
41 
female 24 1 
refractory to 
treatment Azathioprine 
Oral 5-ASA, Topical 
5-ASA, 2000 0 
ing qPCR 
42 
female 27 4 
refractory to 
treatment Azathioprine Infliximab, 6.3 0 
ing qPCR 
43 
female 26 0 
refractory to 
treatment 
Azathioprine, 
150 
Oral 5-ASA, 
Calcium, VitD 2 
ing qPCR 
44 
female 27 1 
refractory to 
treatment Azathioprine 
Infliximab, 5.1, , 
Calcium, VitD 3 
ing qPCR 
45 
female 28 2 
refractory to 
treatment 
Azathioprine 
Oral 5-ASA, 4000, 
Infliximab, 5, 
Magnes, Calcium 8 
ing qPCR 
46 
male 39 4 
refractory to 
treatment Azathioprine 
Topical 5-ASA, Oral 
5-ASA 7 
ing qPCR 
47 
male 40 5 
refractory to 
treatment 
Azathioprine 
Oral 5-ASA, 4000, 
Topical 5-ASA, 
4000, Mutaflor 6 
ing qPCR 
48 
male 41 6 
refractory to 
treatment 
Azathioprine 
Oral 5-ASA, 4000, 
Topical 5-ASA, 
4000 3 
ing qPCR 
49 
male 42 8 
refractory to 
treatment Azathioprine Oral 5-ASA, 4000 7 
ing qPCR 
50 
female 
29 9 refractory to 
treatment 
Azathioprine No - ing qPCR 
51 
male 
41 12 refractory to 
treatment 
Azathioprine No - ing qPCR 
52 male 60 5 refractory to 
treatment, Crohn’s 
disease 
Purinethol 
50 mg 
 
Budenofalk foam 
Salofalk sup. 
Mutaflor 
Alendronat 70 mg / 
week 
Dancor 10 mg po, 
Amiodarone 200 mg 
po, Nebivolol 5 mg 
po, Pravalotin 20 
mg po 
- Abdominal pain (mild but increasing) 
Stool (5 x / day), blood contents 
Calprotectin 770 μg / g stool 
qPCR 
53 male 28 5 refractory to 
treatment, colitis 
ulcerosa 
Imurek 
50 mg 
Salofalk 1.5 g 
Budenofalk foam 
Salofalk supp. 1g 
6 Multiple stool (5 – 6 x / day) 
Abdominal pain (mild) 
PI / annexin V 
qPCR 
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54 male 45 2 refractory to 
treatment, colitis 
ulcerosa 
Imurek 
150 mg 
Prednison 20 mg 
Calcimagon 
Salofalk 3 g 
Salofalk supp. 
Salofalk foam 
Scheriproct 
ointment 
- Multiple stool (10 x / day) 
Stool is diluted and/or blood contents 
Abdominal pain (mild) 
Perianal pain 
Episodes of incontinence 
PI / annexin V  
qPCR 
55 male 30 4 refractory to 
treatment, Crohn’s 
disease 
Imurek 
50 mg 
No A:1, L:1, 
B:1 
Watery diarrhea 
Multiple stool (2 – 10 x / day) 
 
PI / annexin V  
qPCR 
56 female 40 22 refractory to 
treatment, colitis 
ulcerosa 
AZA 
100 mg 
5ASA oral 4.5 g 
vitamin D 
corticosteroids 
6 Evacuation of mucus since two weeks 
Multiple stool 
Lower abdominal pain (moderate) 
qPCR 
MTX = methotrexat, CS = cyclosporine, NA = not applicable, ing = information not interrogated 
Supplementary table 1: Characteristics of healthy controls and patients with IBD 
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